Protection against a lethal H5N1 influenza challenge by intranasal immunization with virus-like particles containing 2009 pandemic H1N1 neuraminidase in mice
Identifieur interne : 000784 ( Pmc/Curation ); précédent : 000783; suivant : 000785Protection against a lethal H5N1 influenza challenge by intranasal immunization with virus-like particles containing 2009 pandemic H1N1 neuraminidase in mice
Auteurs : Judith D. Easterbrook [États-Unis] ; Louis M. Schwartzman [États-Unis] ; Jin Gao [États-Unis] ; John C. Kash [États-Unis] ; David M. Morens [États-Unis] ; Laura Couzens [États-Unis] ; Hongquan Wan [États-Unis] ; Maryna C. Eichelberger [États-Unis] ; Jeffery K. Taubenberger [États-Unis]Source :
- Virology [ 0042-6822 ] ; 2012.
Abstract
Highly pathogenic H5N1 influenza shares the same neuraminidase (NA) subtype with the 2009 pandemic (H1N1pdm09), and cross-reactive NA immunity might protect against or mitigate lethal H5N1 infection. In this study, mice were either infected with a sublethal dose of H1N1pdm09 or were vaccinated and boosted with virus-like particles (VLP) consisting of the NA and matrix proteins, standardized by NA activity and administered intranasally, and were then challenged with a lethal dose of HPAI H5N1 virus. Mice previously infected with H1N1pdm09 survived H5N1 challenge with no detectable virus or respiratory tract pathology on day 4. Mice immunized with H5N1 or H1N1pdm09 NA VLPs were also fully protected from death, with a 100-fold and 10-fold reduction in infectious virus, respectively, and reduced pathology in the lungs. Human influenza vaccines that elicit not only HA, but also NA immunity may provide enhanced protection against the emergence of seasonal and pandemic viruses.
Url:
DOI: 10.1016/j.virol.2012.06.003
PubMed: 22727831
PubMed Central: 3725556
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000784
Links to Exploration step
PMC:3725556Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Protection against a lethal H5N1 influenza challenge by intranasal immunization with virus-like particles containing 2009 pandemic H1N1 neuraminidase in mice</title><author><name sortKey="Easterbrook, Judith D" sort="Easterbrook, Judith D" uniqKey="Easterbrook J" first="Judith D." last="Easterbrook">Judith D. Easterbrook</name><affiliation wicri:level="1"><nlm:aff id="A1">Viral Pathogenesis and Evolution Section, Laboratory of Infectious Diseases, National Institutes of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Viral Pathogenesis and Evolution Section, Laboratory of Infectious Diseases, National Institutes of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD</wicri:regionArea></affiliation></author><author><name sortKey="Schwartzman, Louis M" sort="Schwartzman, Louis M" uniqKey="Schwartzman L" first="Louis M." last="Schwartzman">Louis M. Schwartzman</name><affiliation wicri:level="1"><nlm:aff id="A1">Viral Pathogenesis and Evolution Section, Laboratory of Infectious Diseases, National Institutes of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Viral Pathogenesis and Evolution Section, Laboratory of Infectious Diseases, National Institutes of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD</wicri:regionArea></affiliation></author><author><name sortKey="Gao, Jin" sort="Gao, Jin" uniqKey="Gao J" first="Jin" last="Gao">Jin Gao</name><affiliation wicri:level="1"><nlm:aff id="A2">Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland</wicri:regionArea></affiliation></author><author><name sortKey="Kash, John C" sort="Kash, John C" uniqKey="Kash J" first="John C." last="Kash">John C. Kash</name><affiliation wicri:level="1"><nlm:aff id="A1">Viral Pathogenesis and Evolution Section, Laboratory of Infectious Diseases, National Institutes of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Viral Pathogenesis and Evolution Section, Laboratory of Infectious Diseases, National Institutes of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD</wicri:regionArea></affiliation></author><author><name sortKey="Morens, David M" sort="Morens, David M" uniqKey="Morens D" first="David M." last="Morens">David M. Morens</name><affiliation wicri:level="1"><nlm:aff id="A3">Office of the Director, National Institutes of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Office of the Director, National Institutes of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD</wicri:regionArea></affiliation></author><author><name sortKey="Couzens, Laura" sort="Couzens, Laura" uniqKey="Couzens L" first="Laura" last="Couzens">Laura Couzens</name><affiliation wicri:level="1"><nlm:aff id="A2">Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland</wicri:regionArea></affiliation></author><author><name sortKey="Wan, Hongquan" sort="Wan, Hongquan" uniqKey="Wan H" first="Hongquan" last="Wan">Hongquan Wan</name><affiliation wicri:level="1"><nlm:aff id="A2">Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland</wicri:regionArea></affiliation></author><author><name sortKey="Eichelberger, Maryna C" sort="Eichelberger, Maryna C" uniqKey="Eichelberger M" first="Maryna C." last="Eichelberger">Maryna C. Eichelberger</name><affiliation wicri:level="1"><nlm:aff id="A2">Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland</wicri:regionArea></affiliation></author><author><name sortKey="Taubenberger, Jeffery K" sort="Taubenberger, Jeffery K" uniqKey="Taubenberger J" first="Jeffery K." last="Taubenberger">Jeffery K. Taubenberger</name><affiliation wicri:level="1"><nlm:aff id="A1">Viral Pathogenesis and Evolution Section, Laboratory of Infectious Diseases, National Institutes of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Viral Pathogenesis and Evolution Section, Laboratory of Infectious Diseases, National Institutes of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">22727831</idno><idno type="pmc">3725556</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3725556</idno><idno type="RBID">PMC:3725556</idno><idno type="doi">10.1016/j.virol.2012.06.003</idno><date when="2012">2012</date><idno type="wicri:Area/Pmc/Corpus">000784</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000784</idno><idno type="wicri:Area/Pmc/Curation">000784</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000784</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Protection against a lethal H5N1 influenza challenge by intranasal immunization with virus-like particles containing 2009 pandemic H1N1 neuraminidase in mice</title><author><name sortKey="Easterbrook, Judith D" sort="Easterbrook, Judith D" uniqKey="Easterbrook J" first="Judith D." last="Easterbrook">Judith D. Easterbrook</name><affiliation wicri:level="1"><nlm:aff id="A1">Viral Pathogenesis and Evolution Section, Laboratory of Infectious Diseases, National Institutes of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Viral Pathogenesis and Evolution Section, Laboratory of Infectious Diseases, National Institutes of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD</wicri:regionArea></affiliation></author><author><name sortKey="Schwartzman, Louis M" sort="Schwartzman, Louis M" uniqKey="Schwartzman L" first="Louis M." last="Schwartzman">Louis M. Schwartzman</name><affiliation wicri:level="1"><nlm:aff id="A1">Viral Pathogenesis and Evolution Section, Laboratory of Infectious Diseases, National Institutes of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Viral Pathogenesis and Evolution Section, Laboratory of Infectious Diseases, National Institutes of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD</wicri:regionArea></affiliation></author><author><name sortKey="Gao, Jin" sort="Gao, Jin" uniqKey="Gao J" first="Jin" last="Gao">Jin Gao</name><affiliation wicri:level="1"><nlm:aff id="A2">Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland</wicri:regionArea></affiliation></author><author><name sortKey="Kash, John C" sort="Kash, John C" uniqKey="Kash J" first="John C." last="Kash">John C. Kash</name><affiliation wicri:level="1"><nlm:aff id="A1">Viral Pathogenesis and Evolution Section, Laboratory of Infectious Diseases, National Institutes of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Viral Pathogenesis and Evolution Section, Laboratory of Infectious Diseases, National Institutes of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD</wicri:regionArea></affiliation></author><author><name sortKey="Morens, David M" sort="Morens, David M" uniqKey="Morens D" first="David M." last="Morens">David M. Morens</name><affiliation wicri:level="1"><nlm:aff id="A3">Office of the Director, National Institutes of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Office of the Director, National Institutes of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD</wicri:regionArea></affiliation></author><author><name sortKey="Couzens, Laura" sort="Couzens, Laura" uniqKey="Couzens L" first="Laura" last="Couzens">Laura Couzens</name><affiliation wicri:level="1"><nlm:aff id="A2">Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland</wicri:regionArea></affiliation></author><author><name sortKey="Wan, Hongquan" sort="Wan, Hongquan" uniqKey="Wan H" first="Hongquan" last="Wan">Hongquan Wan</name><affiliation wicri:level="1"><nlm:aff id="A2">Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland</wicri:regionArea></affiliation></author><author><name sortKey="Eichelberger, Maryna C" sort="Eichelberger, Maryna C" uniqKey="Eichelberger M" first="Maryna C." last="Eichelberger">Maryna C. Eichelberger</name><affiliation wicri:level="1"><nlm:aff id="A2">Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland</wicri:regionArea></affiliation></author><author><name sortKey="Taubenberger, Jeffery K" sort="Taubenberger, Jeffery K" uniqKey="Taubenberger J" first="Jeffery K." last="Taubenberger">Jeffery K. Taubenberger</name><affiliation wicri:level="1"><nlm:aff id="A1">Viral Pathogenesis and Evolution Section, Laboratory of Infectious Diseases, National Institutes of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Viral Pathogenesis and Evolution Section, Laboratory of Infectious Diseases, National Institutes of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD</wicri:regionArea></affiliation></author></analytic><series><title level="j">Virology</title><idno type="ISSN">0042-6822</idno><idno type="eISSN">1096-0341</idno><imprint><date when="2012">2012</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><title>Summary</title><p id="P1">Highly pathogenic H5N1 influenza shares the same neuraminidase (NA) subtype with the 2009 pandemic (H1N1pdm09), and cross-reactive NA immunity might protect against or mitigate lethal H5N1 infection. In this study, mice were either infected with a sublethal dose of H1N1pdm09 or were vaccinated and boosted with virus-like particles (VLP) consisting of the NA and matrix proteins, standardized by NA activity and administered intranasally, and were then challenged with a lethal dose of HPAI H5N1 virus. Mice previously infected with H1N1pdm09 survived H5N1 challenge with no detectable virus or respiratory tract pathology on day 4. Mice immunized with H5N1 or H1N1pdm09 NA VLPs were also fully protected from death, with a 100-fold and 10-fold reduction in infectious virus, respectively, and reduced pathology in the lungs. Human influenza vaccines that elicit not only HA, but also NA immunity may provide enhanced protection against the emergence of seasonal and pandemic viruses.</p></div></front></TEI><pmc article-type="research-article"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
<pmc-dir>properties manuscript</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-journal-id">0110674</journal-id><journal-id journal-id-type="pubmed-jr-id">8015</journal-id><journal-id journal-id-type="nlm-ta">Virology</journal-id><journal-id journal-id-type="iso-abbrev">Virology</journal-id><journal-title-group><journal-title>Virology</journal-title></journal-title-group><issn pub-type="ppub">0042-6822</issn><issn pub-type="epub">1096-0341</issn></journal-meta><article-meta><article-id pub-id-type="pmid">22727831</article-id><article-id pub-id-type="pmc">3725556</article-id><article-id pub-id-type="doi">10.1016/j.virol.2012.06.003</article-id><article-id pub-id-type="manuscript">NIHMS384774</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Protection against a lethal H5N1 influenza challenge by intranasal immunization with virus-like particles containing 2009 pandemic H1N1 neuraminidase in mice</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Easterbrook</surname><given-names>Judith D.</given-names></name><xref ref-type="aff" rid="A1">a</xref><xref ref-type="corresp" rid="cor1">#</xref></contrib><contrib contrib-type="author"><name><surname>Schwartzman</surname><given-names>Louis M.</given-names></name><xref ref-type="aff" rid="A1">a</xref></contrib><contrib contrib-type="author"><name><surname>Gao</surname><given-names>Jin</given-names></name><xref ref-type="aff" rid="A2">b</xref></contrib><contrib contrib-type="author"><name><surname>Kash</surname><given-names>John C.</given-names></name><xref ref-type="aff" rid="A1">a</xref></contrib><contrib contrib-type="author"><name><surname>Morens</surname><given-names>David M.</given-names></name><xref ref-type="aff" rid="A3">c</xref></contrib><contrib contrib-type="author"><name><surname>Couzens</surname><given-names>Laura</given-names></name><xref ref-type="aff" rid="A2">b</xref></contrib><contrib contrib-type="author"><name><surname>Wan</surname><given-names>Hongquan</given-names></name><xref ref-type="aff" rid="A2">b</xref></contrib><contrib contrib-type="author"><name><surname>Eichelberger</surname><given-names>Maryna C.</given-names></name><xref ref-type="aff" rid="A2">b</xref></contrib><contrib contrib-type="author"><name><surname>Taubenberger</surname><given-names>Jeffery K.</given-names></name><xref ref-type="aff" rid="A1">a</xref></contrib></contrib-group><aff id="A1"><label>a</label>Viral Pathogenesis and Evolution Section, Laboratory of Infectious Diseases, National Institutes of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA</aff><aff id="A2"><label>b</label>Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland, USA</aff><aff id="A3"><label>c</label>Office of the Director, National Institutes of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA</aff><author-notes><corresp id="cor1"><label>#</label>Corresponding Author: Judith D. Easterbrook, PhD, Laboratory of Infectious Diseases, NIAID, NIH, 33 North Drive, MSC 3203, Bethesda, MD, 20892-3203, USA. <email>easterbrookjd@niaid.nih.gov</email>; Telephone: (301) 443-5948; Fax: (301) 480-1696</corresp></author-notes><pub-date pub-type="nihms-submitted"><day>13</day><month>6</month><year>2012</year></pub-date><pub-date pub-type="epub"><day>22</day><month>6</month><year>2012</year></pub-date><pub-date pub-type="ppub"><day>10</day><month>10</month><year>2012</year></pub-date><pub-date pub-type="pmc-release"><day>10</day><month>10</month><year>2013</year></pub-date><volume>432</volume><issue>1</issue><fpage>39</fpage><lpage>44</lpage><permissions><copyright-statement>© 2012 Elsevier Inc. All rights reserved.</copyright-statement><copyright-year>2012</copyright-year></permissions><abstract><title>Summary</title><p id="P1">Highly pathogenic H5N1 influenza shares the same neuraminidase (NA) subtype with the 2009 pandemic (H1N1pdm09), and cross-reactive NA immunity might protect against or mitigate lethal H5N1 infection. In this study, mice were either infected with a sublethal dose of H1N1pdm09 or were vaccinated and boosted with virus-like particles (VLP) consisting of the NA and matrix proteins, standardized by NA activity and administered intranasally, and were then challenged with a lethal dose of HPAI H5N1 virus. Mice previously infected with H1N1pdm09 survived H5N1 challenge with no detectable virus or respiratory tract pathology on day 4. Mice immunized with H5N1 or H1N1pdm09 NA VLPs were also fully protected from death, with a 100-fold and 10-fold reduction in infectious virus, respectively, and reduced pathology in the lungs. Human influenza vaccines that elicit not only HA, but also NA immunity may provide enhanced protection against the emergence of seasonal and pandemic viruses.</p></abstract><funding-group><award-group><funding-source country="United States">National Institute of Allergy and Infectious Diseases Extramural Activities : NIAID</funding-source><award-id>Z99 AI999999 || AI</award-id></award-group><award-group><funding-source country="United States">National Institute of Allergy and Infectious Diseases Extramural Activities : NIAID</funding-source><award-id>Z01 AI000986-01 || AI</award-id></award-group></funding-group></article-meta></front></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/H2N2V1/Data/Pmc/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000784 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Curation/biblio.hfd -nk 000784 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= H2N2V1
|flux= Pmc
|étape= Curation
|type= RBID
|clé= PMC:3725556
|texte= Protection against a lethal H5N1 influenza challenge by intranasal immunization with virus-like particles containing 2009 pandemic H1N1 neuraminidase in mice
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Curation/RBID.i -Sk "pubmed:22727831" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Curation/biblio.hfd \
| NlmPubMed2Wicri -a H2N2V1
| This area was generated with Dilib version V0.6.33. |  |